List of Excipients in Branded Drug IVABRADINE

« Back to Dashboard

Generic Drugs Containing IVABRADINE

Company	Ingredient	NDC	Excipient
Camber Pharmaceuticals Inc	ivabradine	31722-053	GLYCERIN
Camber Pharmaceuticals Inc	ivabradine	31722-053	HYPROMELLOSE 2910
Camber Pharmaceuticals Inc	ivabradine	31722-053	LACTOSE MONOHYDRATE
Camber Pharmaceuticals Inc	ivabradine	31722-053	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in IVABRADINE?

# Of NDCs	Excipient
2	ALUMINUM OXIDE
4	ANHYDROUS LACTOSE
2	BUTYLATED HYDROXYANISOLE
2	BUTYLATED HYDROXYTOLUENE

Ivabradine Excipient Strategy and Commercial Opportunities

Last updated: October 2, 2026

Ivabradine has a favorable formulation profile for generic and lifecycle development because the drug is marketed in both immediate-release tablets and an oral solution. The strongest commercial opportunities are pediatric and dysphagia-friendly liquid formulations, differentiated tablet excipient systems, lactose-free products, and manufacturing platforms that improve dose uniformity and stability.

Corlanor, the U.S. reference product, is approved for adults with stable symptomatic heart failure with reduced ejection fraction and for certain pediatric patients with stable symptomatic heart failure due to dilated cardiomyopathy. The product is marketed as 5 mg and 7.5 mg tablets and as a 5 mg/5 mL oral solution equivalent to 1 mg/mL [1].

What excipients are used in ivabradine products?

Ivabradine excipients differ by dosage form, manufacturer and jurisdiction. The U.S. Corlanor tablet uses a conventional immediate-release formulation containing lactose monohydrate, maize starch, maltodextrin, magnesium stearate and colloidal silicon dioxide. The film coating contains standard coating excipients [1].

The oral solution uses an aqueous vehicle and sweetening and pH-adjustment components suitable for pediatric administration. The exact inactive-ingredient profile should be assessed against the current FDA label and the relevant national product information before development decisions are made [1, 2].

Dosage form	Reference product	Key formulation requirements	Main commercial opportunity
Immediate-release tablet	Corlanor 5 mg and 7.5 mg	Rapid disintegration, dose uniformity, swallowability	Generic substitution and differentiated excipient platforms
Oral solution	Corlanor 5 mg/5 mL	Palatability, chemical stability, microbial control, dosing accuracy	Pediatric, dysphagia and feeding-tube markets
Extemporaneous liquid	Compounded products	Suspension stability and dose recovery	Lower-cost pharmacy and hospital alternatives
Modified-release product	Not the reference standard	Release control and clinical bridging	Higher regulatory and development risk

Ivabradine is generally administered with food because food affects exposure. This requirement makes excipient selection and dissolution testing commercially relevant, even for a conventional immediate-release tablet [1].

How does ivabradine’s physicochemical profile affect excipient selection?

Ivabradine is marketed as ivabradine hydrochloride. The molecule is basic and is handled in an acidic salt form to support pharmaceutical processing and oral delivery. The principal excipient issues are not complex controlled release or biologic stabilization. They are powder flow, content uniformity, dissolution, palatability, chemical stability and dose flexibility.

Immediate-release tablet design

The reference tablet uses a low-complexity formulation. A generic developer can generally evaluate:

• Lactose-based direct compression
• Lactose-free formulations using microcrystalline cellulose, mannitol or dibasic calcium phosphate
• Maize-starch or pregelatinized-starch disintegration systems
• Croscarmellose sodium or crospovidone as higher-performance superdisintegrants
• Colloidal silicon dioxide for flow and magnesium stearate for lubrication
• Hypromellose-based film coatings for appearance, protection and swallowability

The critical quality attributes are assay, content uniformity, degradation products, dissolution, hardness, friability, disintegration and stability. Excessive hydrophobic lubrication can slow dissolution, particularly when magnesium stearate levels or blending times are high.

A formulation that matches the reference product’s dissolution behavior without duplicating its full excipient composition is likely to be commercially preferable. The objective is therapeutic equivalence, manufacturing robustness and low raw-material cost.

Oral solution design

The liquid formulation has a broader excipient problem set. Developers must control:

• Ivabradine solubility across the product’s pH range
• Chemical degradation during shelf life
• Palatability and aftertaste
• Microbial quality
• Dose-measuring accuracy
• Compatibility with oral syringes, enteral feeding tubes and dosing cups
• Container closure integrity and light exposure

The pediatric product must support accurate administration of low volumes. A 1 mg/mL concentration simplifies weight-based dosing and reduces calculation errors compared with more dilute preparations.

A commercial liquid should be evaluated with oral syringes rather than relying only on the supplied cup. Syringe compatibility, residual volume, dose recovery and adsorption to plastic components can affect delivered dose.

What formulation patents protect ivabradine products?

Ivabradine’s original active-ingredient patent protection has largely expired in major markets, which allows generic development. Current competitive protection is more likely to arise from formulation, manufacturing, regulatory exclusivity or product-specific intellectual property than from the core molecule.

Potentially relevant patent categories include:

1. Oral solution compositions with specific pH, sweeteners, preservatives or stabilizers.
2. Pediatric dosing systems and calibrated delivery devices.
3. Taste-masked granules, multiparticulates or orally disintegrating tablets.
4. Processes for controlling polymorphism, particle size or crystallinity.
5. Combination products containing ivabradine with other cardiovascular agents.
6. Specific methods of use in pediatric heart failure or related patient populations.
7. Packaging systems designed to improve liquid stability or dose accuracy.

A freedom-to-operate review should distinguish between patents covering ivabradine hydrochloride itself, formulation claims, manufacturing processes, dosing devices and method-of-use claims. Formulation patents have greater practical importance for a liquid generic than for a standard immediate-release tablet.

What is the Orange Book status of Corlanor?

Corlanor is listed in the FDA Orange Book under NDA 206192. The regulatory review should examine the current Orange Book entry for listed patents, use codes and any remaining exclusivity associated with the approved product [3].

A Paragraph IV challenge would typically target listed patents that remain relevant to the approved product or its use. For a conventional ivabradine tablet, the principal commercial question is whether any enforceable formulation or method-of-use patent can delay approval or launch. For an oral solution, the risk assessment should focus on liquid-composition and pediatric-use claims.

The core commercial exposure is therefore likely to be determined by:

• The exact dosage form submitted
• The proposed labeling
• Any carve-out from patented use
• The Orange Book listing at the time of filing
• The sponsor’s litigation and settlement position
• FDA approval timing and any remaining regulatory exclusivity

When does ivabradine lose exclusivity?

Ivabradine’s U.S. approval occurred on April 15, 2015. The product received FDA approval for adult heart failure and subsequently supported pediatric use through supplemental regulatory activity [1, 4].

The original active-ingredient exclusivity period is no longer the primary market barrier in the United States or Europe. Generic and multisource competition has developed in several markets. The timing of entry still varies by country because national patent terms, supplementary protection certificates, pediatric extensions, regulatory data exclusivity and local filing practices differ.

Market issue	Commercial effect
Expired core compound protection	Supports generic tablet development
Product-specific formulation claims	Can delay or narrow liquid competition
Pediatric regulatory protections	May affect labeled pediatric competition
National patent and SPC rules	Create country-specific launch differences
Regulatory approval timing	Determines first-to-market advantage

No single global expiry date governs ivabradine. A country-by-country launch plan is required.

What commercial opportunities exist for ivabradine excipients?

Pediatric oral liquid

The strongest opportunity is a ready-to-use oral solution or a stable liquid concentrate with a well-designed dosing device. Pediatric heart failure patients may have difficulty swallowing tablets, and caregivers require dose flexibility as body weight changes.

A differentiated liquid can compete on:

• Low dosing error
• Better taste
• Longer in-use stability
• Lower storage burden
• Compatibility with oral syringes
• Reduced need for pharmacy compounding
• Clear labeling for weight-based administration

The commercial value is higher where pediatric heart-failure treatment is concentrated in specialist centers and where compounded liquids are common.

Lactose-free tablets

The reference tablet contains lactose. A lactose-free generic could target patients with lactose intolerance, excipient restrictions or preference for a simplified formulation. This is unlikely to support a large standalone premium, but it can improve formulary access and differentiate a multisource product.

Mannitol, microcrystalline cellulose and starch-based systems are practical candidates. Developers must verify that substitution does not change dissolution, mechanical strength or stability.

Orodispersible and mini-tablet formats

An orally disintegrating tablet or mini-tablet could address pediatric and geriatric swallowing problems. The regulatory burden is higher than for a standard generic tablet because taste, in-mouth disintegration, dose uniformity and bioequivalence may require additional work.

A mini-tablet strategy may be more practical than an orally disintegrating tablet where flexible dosing is important. Multiparticulate dosing can support weight-based administration, but it creates greater manufacturing and content-uniformity complexity.

Taste-masked granules

Taste masking can use polymer coatings, ion-exchange systems or lipid-based barriers. Ivabradine’s bitter or unpleasant taste profile makes this relevant for liquid and orally disintegrating products.

The main development risk is delayed release. Taste-masking technology must preserve immediate-release behavior and avoid excipient interactions that alter absorption.

Improved packaging and delivery systems

A liquid product can gain commercial value through packaging rather than a novel excipient alone. Useful features include:

• Bottle adapters for oral syringes
• Child-resistant closures
• Light-protective containers
• Unit-dose packaging
• Low-residual-volume syringes
• Tamper-evident systems
• Dosing charts based on body weight

These features can support hospital procurement and reduce medication-use errors.

How strong is the ivabradine patent estate?

The patent estate is stronger for differentiated dosage forms than for the basic active ingredient. A conventional immediate-release tablet is likely to face the highest generic competition and the lowest patent differentiation.

Product strategy	Patent exposure	Development complexity	Commercial attractiveness
Standard tablet	Low to moderate	Low	High-volume, price-driven
Lactose-free tablet	Low to moderate	Low to medium	Moderate
Oral solution	Moderate	Medium	High in pediatric markets
Taste-masked liquid	Moderate to high	Medium to high	High if clinically differentiated
Orally disintegrating tablet	Moderate	Medium to high	Selective
Modified-release product	High	High	Uncertain

A formulation patent is most valuable when it creates a clinically meaningful or procurement-relevant advantage. A narrow excipient substitution without better stability, taste, dosing or patient usability is unlikely to create durable pricing power.

Which companies are challenging ivabradine’s market?

Competition comes from several groups:

• Originator and license partners commercializing Corlanor or Procoralan
• Generic pharmaceutical companies producing ivabradine tablets
• Regional manufacturers supplying European and emerging markets
• Contract development and manufacturing organizations developing liquid products
• Hospital pharmacies and compounding facilities preparing alternative liquids

The generic market is likely to remain fragmented because ivabradine is a specialty cardiovascular product rather than a broad primary-care volume medicine. A first approved liquid, a pediatric-focused presentation or a reliable low-cost tablet can gain share without requiring a major molecular innovation.

What is the FDA regulatory pathway for generic ivabradine?

A standard tablet would generally be developed through an abbreviated new drug application when the reference product and dosage form are eligible for an ANDA pathway. The product must demonstrate pharmaceutical equivalence and bioequivalence, meet current good manufacturing practice requirements and address labeling differences permitted under the applicable framework [5].

An oral solution may have a simpler bioequivalence path if it is qualitatively and quantitatively equivalent to the reference solution and meets relevant regulatory criteria. Differences in inactive ingredients, concentration, pH, preservatives or flavoring can increase the need for comparative studies.

A new dosage form, pediatric formulation or modified-release product could require a more extensive application, including additional clinical or pharmacokinetic evidence.

What litigation and settlement risks affect generic entry?

Ivabradine litigation risk depends on active Orange Book listings and the claims asserted by the reference-product sponsor. A Paragraph IV filing can trigger patent litigation and a statutory stay of FDA approval under the Hatch-Waxman framework if the relevant conditions are met [6].

Settlement terms may include:

• Delayed generic entry
• Authorized-generic supply
• License rights for selected markets
• Restrictions limited to a dosage form
• Carve-outs for patented indications
• Launch rights tied to patent validity or expiration

A tablet sponsor and a liquid sponsor may face different litigation profiles because formulation claims often apply to one dosage form rather than to all ivabradine products.

How does ivabradine compare with competing heart-failure drugs?

Ivabradine occupies a narrow role in heart-failure treatment. It is used to reduce hospitalization risk in selected patients with symptomatic stable chronic heart failure, reduced ejection fraction and elevated sinus heart rate despite appropriate background therapy [1].

Its main commercial comparisons are not direct molecule-to-molecule substitutes. They include beta blockers, angiotensin receptor-neprilysin inhibitors, ACE inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors. These products have broader guideline positioning and larger markets.

Ivabradine’s commercial advantage is targeted use in patients who remain tachycardic in sinus rhythm. Its commercial limitation is the narrower eligible population and the requirement for heart-rate and rhythm selection.

What generic launch scenarios exist for ivabradine?

Standard tablet launch

This is the most likely low-risk entry strategy. The product can compete through price, supply reliability and pharmacy substitution. The principal challenge is margin compression as additional generic manufacturers enter.

Pediatric liquid launch

A liquid entrant can avoid direct price comparison with tablets and compete on administration, dosing accuracy and access. The addressable population is smaller, but product differentiation is stronger.

Authorized-generic or licensed launch

A reference-sponsor-linked product can reduce litigation exposure and provide immediate manufacturing or distribution capabilities. The tradeoff is lower independence and potentially lower gross margin.

Hospital-focused launch

A supplier can target specialist cardiac centers with liquid presentations, dosing devices and technical support. This approach may produce lower national volume but higher adoption within key institutions.

What manufacturing and IP barriers affect ivabradine?

Manufacturing barriers are manageable for tablets but more significant for liquids. Key issues include:

• Consistent assay at low dose
• Powder segregation and content uniformity
• Control of ivabradine degradation
• pH management
• Container compatibility
• Preservative performance
• Taste masking without delayed dissolution
• Reproducible liquid filling
• Cleaning validation and cross-contamination control

IP barriers are concentrated in formulation details, pediatric presentations, manufacturing processes and delivery systems. The most defensible commercial platform will combine a low-cost formulation with a practical administration advantage.

Key Takeaways

• Ivabradine has a relatively accessible generic tablet opportunity because core active-ingredient protection is no longer the main barrier.
• The reference tablet uses conventional excipients, including lactose, maize starch, maltodextrin, magnesium stearate and colloidal silicon dioxide.
• Pediatric oral solution development is the most attractive excipient-led opportunity.
• Taste, pH, stability, microbial control and dosing-device compatibility are the main liquid-development issues.
• Lactose-free tablets offer modest differentiation but limited standalone pricing power.
• Orally disintegrating tablets, mini-tablets and taste-masked granules can support specialty positioning but require additional development work.
• Formulation and method-of-use patents matter more than the expired core compound estate.
• Orange Book review and country-specific patent analysis remain central to Paragraph IV and launch planning.
• The commercial market is narrow but suitable for a focused generic, hospital and pediatric strategy.

FAQs

Can ivabradine be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch-based excipients or other suitable fillers. The replacement must be assessed for dissolution, hardness, friability, stability and bioequivalence.

Is ivabradine suitable for an oral suspension?

Ivabradine can be developed as a liquid suspension or solution, but the preferred format depends on solubility, pH stability, taste and dose uniformity. A true solution is generally easier to dose accurately if chemical stability can be maintained.

What is the most valuable ivabradine formulation patent strategy?

The strongest strategy is usually a patent covering a clinically useful liquid, taste-masked product, dosing system or stability improvement. A narrow claim directed only to an interchangeable excipient is less likely to create durable market protection.

Can a generic ivabradine tablet use different excipients from Corlanor?

Yes. A generic may use different inactive ingredients if it meets applicable pharmaceutical-equivalence, bioequivalence, quality and labeling requirements. Differences that affect absorption, dissolution or tolerability can increase regulatory complexity.

Is there biosimilar risk for ivabradine?

No. Ivabradine is a chemically synthesized small molecule, not a biologic. Competitive risk comes from generic tablets, oral liquids, alternative dosage forms and regional manufacturers rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2024). Corlanor (ivabradine) prescribing information. FDA.

2. European Medicines Agency. (2024). Procoralan: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2015). FDA approves Corlanor to treat heart failure. FDA.

5. U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. FDA.

6. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, 21 U.S.C. § 355(j).